Verastem, Inc.

NASDAQ:VSTM

Biotechnology

Healthcare
$7.41 -0.00%

-$0.00 today

Market cap
$933.77M
Beta
0.27
P/E (TTM)
-2.1
EPS (TTM)
-$1.97
52W Low $3.55High $11.25

Volume 2.87M

Average 2.58M

Returns on capital

Verastem, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-366.2%

avg -247.7%

ROIC

-97.4%

avg -80.7%

ROA

-85.0%

avg -68.9%

Analysis

ROA is currently the strongest return metric at -85.0% versus its period average of -68.9%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Daniel W. Paterson

President, Chief Executive Officer & DirectorUSD 1.24M65——

Michael Glen Kauffman

President of Development & DirectorUSD 930K63——

Daniel Calkins

Chief Financial OfficerUSD 526.15K38123.78K0.18%

Jonathan Pachter

Chief Scientific OfficerUSD 238.18K6862.25K0.09%

Michelle Detwiler

Co-Founder—50——

Nathan Sanburn

Chief Business Officer————

Julissa Viana

Senior Vice President of Corporate Communications, Investor Relations & Patient Advocacy————

Mark J. Wanda

Senior VP of Legal & Chief Compliance Officer————

Lori Horvat

Executive Vice President of Portfolio Strategy & Operations————

Robert A. Weinberg

Co-Founder & Chair of Scientific Advisory Board——363.44K0.52%

Cathy Carew

Chief Organizational Effectiveness Officer————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Oct 1, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

0

$0.00

Sells

32

$1.07M

Net Transaction Value

−$1.07M

Net selling

Most Active

Paterson Dan

22 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Nov 3, 26

Paterson Dan

Direct

Sell$12.5K
Oct 1, 26

Paterson Dan

Direct

Sell$353K
Oct 1, 26

Calkins Daniel

Direct

Sell$20.5K
Sep 21, 26

Calkins Daniel

Direct

Sell$423.5
Aug 3, 26

Paterson Dan

Direct

Sell$7.6K
Jun 22, 26

Paterson Dan

Direct

Sell$87.2K
Jun 22, 26

Calkins Daniel

Direct

Sell$16.9K
Jun 22, 26

Calkins Daniel

Direct

Sell$235.4
May 4, 26

Paterson Dan

Direct

Sell$4.7K
Feb 4, 26

Paterson Dan

Direct

Sell$6.5K

1–10 of 32

Summary

Insiders reported 0 buys worth $0.00 and 32 sells worth $1.07M over the last 12 months. That adds up to net selling of $1.07M. Paterson Dan was the most active insider with 22 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A2 analysts
RevenueN/AN/A+128.4%
+78.3% (5yr)5 analysts
Net IncomeN/AN/AN/A
N/A5 analysts
EBITN/AN/AN/A
N/A5 analysts

Analysis

Recent growth has been strongest in Revenue at +128.4% over three years. Forward estimates point to Revenue at +78.3% (5yr), giving you a quick check on whether expectations are accelerating or cooling.

Competitors

Who does Verastem, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about VSTM's management, answered from reported figures.

Who manages VSTM?

Verastem, Inc. (VSTM) lists 11 active executives. The top listed executive is Michelle Detwiler, Co-Founder.

Are VSTM insiders buying or selling?

Recent insider activity shows net selling of $3.52M.